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ABSTRACT
REPRODUCTIVE FACTORS AND POSTMENOPAUSAL FOLLICLE
STIMULATING HORMONE LEVELS
MAY 2020
REBECCA COSTA, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Elizabeth Bertone-Johnson
Recent studies have shown that postmenopausal follicle stimulating hormone
(FSH) levels may be predictive of future cardiovascular disease risk. However, little is
known about postmenopausal FSH levels, including the level of variation between
women and factors associated with this variation. We assessed the relationship of
multiple reproductive factors with FSH levels among 588 postmenopausal women in the
Kuopio Ischemic Heart Disease Risk Factor Study. Participants were aged 53 to 73 years
and not using hormone therapy at baseline (1998-2001). Reproductive factors were
assessed at baseline, along with FSH levels. After adjustment for sex steroids, adiposity
measures, plasma lipids, blood pressure, and behavioral factors, we observed that women
with 3 or more births and an age at first birth of 25 or later had mean FSH levels that
were significantly 7.6 IU/L lower than those of women with a 1 to 2 births and an age at
first birth of 24 or less. Number of miscarriages was inversely correlated with FSH levels.
Women reporting a 7 or more years of OC use and 4-6 or 7 or more years of HT use each
had significantly higher mean FSH levels than women who had never used OCs or HT. In
summary, multiple reproductive factors were associated with postmenopausal FSH
levels, independent of estradiol, adiposity, and other factors. These findings warrant
replication and further exploration of potential underlying mechanism.
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CHAPTER 1
INTRODUCTION
Recent studies have shown that postmenopausal follicle-stimulating hormone
(FSH) levels may be inversely associated with prevalence of diabetes and atherosclerosis
in postmenopausal women.1,2 Findings from these studies suggest that postmenopausal
FSH levels may be predictive of future cardiovascular disease risk. However, little is
known about postmenopausal FSH levels, including the level of variation between
women and the factors associated with this variation. Given the important role of FSH in
follicle development and ovulation in premenopausal women, we hypothesized that
reproductive history may be associated with postmenopausal FSH levels.3
Follicle-stimulating hormone is involved in menstrual cycle regulation and
fluctuates cyclically during the premenopausal years via feedback with estradiol.3 The
release of FSH by the anterior pituitary stimulates the production of estradiol in the
ovarian follicles. As the follicles mature, estrogen levels rise, creating a negative
feedback effect with the anterior pituitary and causing FSH level to decline. After
estrogen levels decline at the end of the cycle, this negative feedback is broken, and the
cycle repeats.
As menopause approaches and follicular estradiol production declines, FSH levels
increase in order to maintain estrogen levels, although the level of increase in FSH
around the time of the final menstrual period varies among women.4 Previous studies
have shown that that there are three distinct trajectories of FSH change during the
menopausal transition, including low, medium, and high rising. At the conclusion of the
menopausal transition, FSH levels are believed to plateau and gradually decline.1,4 Very
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little is known concerning FSH function in the years after the menopause transition is
complete, though FSH secretion continues and levels between women vary substantially.
Few studies have assessed whether reproductive factors including parity,
pregnancy loss, age at first birth, exogenous hormone use, and gynecologic surgeries may
be associated with postmenopausal FSH levels. One study of 173 sedentary, overweight
postmenopausal women found that nulliparous women had higher FSH levels than parous
women,5 while a study of 270 healthy postmenopausal women found a positive
association between pregnancy termination and FSH.6 The association of other
reproductive factors with FSH, and likelihood of potential confounding by estrogens and
other hormones, have not been investigated. Thus, we evaluated the relation of multiple
reproductive factors and postmenopausal FSH while accounting for other factors
including adiposity, hormones, and behavioral factors among a population of Finnish
women.
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CHAPTER 2
METHODS
2.1 Study Population
The KIHD study is an ongoing population-based cohort study of risk factors
for cardiovascular and metabolic conditions in men and women living in eastern Finland.
Whereas male participants were enrolled in 1984 to 1989, female participants were first
enrolled between March 1998 and February 2001. Women eligible for enrollment were a
random sample of 1173 postmenopausal women living in Kuopio and surrounding rural
communities. Women from four specific age groups were selected: 53-56 years, 59-62
years, 64-68 years, and 71-73 years. Of eligible women, 920 (78.4%) completed baseline
clinical assessments and joined the cohort. Among the nonparticipants, 168 refused
participation, 51 could not be contacted, and 34 were not included for other reasons. The
study protocol was approved by the Research Ethics Committee of the University of
Kuopio. All participants provided written informed consent.

2.2 Questionnaire Assessments
Participants reported data on demographic, behavior, reproductive, and healthrelated factors on questionnaires, which were then reviewed by a trained interviewer for
completeness and clarity. Reproductive factors included age at menarche, history and
duration of oral contraceptive use, number of full-term pregnancies, age at last menses,
and history of hysterectomy and oophorectomy; use of hormone therapy (HT; ever use,
current use and total duration) was also assessed. Postmenopausal status and age at
menopause were defined by the absence of menses for at least 12 months, or at the time
of oophorectomy for women who reported having undergone surgery prior to menopause.
3

Physical activity was assessed with the KIHD 12-Month Leisure Time Physical Activity
History questionnaire and was used to estimate amount of physical activity (metabolic
equivalent of task hours) per day. Each participant also completed a detailed alcohol use
questionnaire which was used to estimate alcohol intake.

2.3 Blood Collection and Biochemical Measurements
At the clinical interview, fasting blood samples were collected between 8:00 AM
and 10:00 AM, after participants had abstained from eating or smoking cigarettes for 12
hours and consuming alcohol for 3 days.2 Plasma was separated from other blood
components within 60 minutes and stored at −20°C or−80°C until assay. Samples were
assayed for FSH between June 2001 and February 2002. Serum FSH concentration was
determined with a sandwich technique applying an immunoradiometric assay
manufactured by Diagnostic Products Corporation (Coat-A-Count FSH IRMA;
Diagnostic Products Corporation, Los Angeles, California). Serum 17-B-estradiol was
assayed between 1999 and 2001 with a radioimmunoassay manufactured by DiaSorin
(DiaSorin S.p.A., Stillwater, Minnesota). Serum testosterone (17B-hydroxy-4-androsten3-one) was determined with the Spectria Testosterone radioimmunoassay kit (Orion
Diagnostic, Espoo, Finland). I label measurements for FSH, E2, and testosterone were
carried out by gamma counter Wallac 1261 MultiGamma using a RiaCalc LM Evaluation
Program. Coefficients of variation (CVs) were 5% for FSH, 7.6% to 12.0% for E2, and
7.9% to 12.2% for testosterone.
Samples from all participants were assayed for high-density lipoprotein (HDL)
and low-density lipoprotein (LDL) cholesterol, and triglycerides using laboratory
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methods described in detail previously. CVs were 5.2% for LDL, 9.2% for HDL, and
1.9% for triglycerides.

2.4 Clinical Measures
At baseline, resting systolic and diastolic blood pressure were calculated as the
average of six measurements, including three made supine after 5 minutes resting; one
made standing; and two made sitting, with 5 minutes between measures. Height and
weight were directly measured and used to calculate BMI (weight in kg/square of height
in m). Waist and hip circumferences were measured with a standard measuring tape and
used to calculate waist-to-hip ratio. All measurements were then repeated at the followup visit.

2.5 Statistical Analysis
The present analysis was limited to women not using HT at baseline (n=593).
Additionally, five participants did not have FSH measurements and were excluded,
leaving 588 women as the analytic population.
FSH was normally distributed and did not require transformation. We divided the
participants by age based on the categories used for participant recruitment (53-56, 59-62,
64-68, 71-73) and compared mean FSH levels between the four categories using analysis
of variance (ANOVA).
To determine if participant characteristics were related to FSH levels, we
evaluated these associations using linear regression. We then used linear regression to
assess how reproductive factors, including number of full-term births, history of
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spontaneous abortion, timing of first pregnancy, age at menarche, age at menopause,
number of reproductive years, OC use and duration, past HT use and duration, and
gynecologic surgical history (i.e., oophorectomy and hysterectomy), were associated with
FSH. Indictor variables were created for fixed categories. To account for confounding by
demographic, hormonal and behavioral factors, we built two multivariate models. In the
first, we adjusted for year of study entry, age, enrollment age category ,estradiol,
testosterone, and SHBG. Model 3 included model 2 variables plus current smoking, packyears of smoking, physical activity, alcohol use (g/week), waist:hip ratio, BMI, systolic
and diastolic blood pressure, triglycerides, and LDL and HDL cholesterol. Information on
variable categorizations are included in table footnotes.
We then conducted stratified analyses to evaluate whether associations between
reproductive factors and FSH levels varied by age (53-62 versus 64-73 years) and BMI
(normal weight, overweight, obese).

6

CHAPTER 3
RESULTS
The distribution of FSH by participant age group is presented in Table 1. Younger
postmenopausal women (ages 53-56 years) had modestly higher mean FSH levels than
older women (ages 71-73 years), although the means were not significantly lower among
older women. Within each each group, there was a large variation in FSH levels. As
shown in table 2, FSH levels were inversely associated with age, BMI, and waist-to-hip
ratio, but were not associated with physical activity, alcohol intake, and smoking. FSH
was significantly inversely associated with systolic blood pressure, estradiol, and
testosterone, and significantly positively associated with plasma lipids and SHBG.
Association of pregnancy-related reproductive factors with FSH levels are
presented in Table 3. In unadjusted analyses, mean age at first birth was inversely
associated with FSH level. Women with a higher parity had lower FSH levels than
women of a lower parity (model 1; P for trend 0.006). In the evaluation of age at first
birth and parity simultaneously, both factors appeared to be independently inversely
associated with FSH. Adjustment for sex steroids and SHBG attenuated results (model 2),
but mean FSH levels remained significantly lower in women with three or more
pregnancies and a later age at first birth than the reference groups (women with 1-2 births
and first birth at <25 years). After additional adjustment for adiposity, behavioral, and
clinical factors (model 3), a significant inverse trend for remained for parity and was
suggestive for age at first birth. In the analysis of both factors simultaneously, mean FSH
levels were significantly 7.6 IU/L lower among women with 3 or more births and first
birth at age 25 or later. The reported number of miscarriages among participants ranged
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from 0 to 5, with n=104 women reporting 1 and n=30 reporting 2 or more miscarriages.
Number of miscarriages was inversely associated with FSH level in each set of models.
Table 4 presents results on the relation of gynecologic surgeries and benign
gynecologic conditions with FSH levels. History of hysterectomy, but not oophorectomy,
was significantly inversely associated with FSH level in our unadjusted analysis. Women
with a history uterine myoma had lower FSH levels than women who did not, while a
history of endometriosis was not associated with FSH levels. Results for all of these
relations were attenuated and no longer significant after adjustment for sex steroids and
SHBG (model 2) and in our fully adjusted model (model 3).
Associations of FSH levels with age at menarche and menopause, along with
exogenous hormone use, are presented in Table 5. Age at last menses and age at
menarche were not significantly associated with FSH level. Women with a history of HT
use had higher FSH levels than women without HT use, with evidence of a dose-response
relationship with duration of use. Women with the longest duration of OC use had higher
FSH levels than women who never used OC, although no dose-response relationship was
evident. Adjustment for sex steroids and SHBG (model 2) attenuated results, but mean
FSH levels remained significantly higher for a long duration of HT use, and nonsignificantly higher with a longer duration of OC use. In our fully adjusted model (model
3), women reporting OC use for 7 or more years had significantly higher mean FSH
levels than women who had never used OCs. Women who used HT for 4-6 years or 7+
years both had a significantly higher mean FSH levels than women who had never used
HT. Age at menarche and last menses remained unassociated with FSH levels.
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To determine if associations between the main reproductive factors and FSH
differed between younger and older postmenopausal women, we stratified women by age
group (ages 53-62 years vs. 64-73 years) and reran our fully adjusted model (Table 6). In
the evaluation of age at first birth and parity simultaneously, associations for higher
parity and higher age at first birth were strong and significant among younger
postmenopausal women, but not among older postmenopausal women. Long duration of
OC use was similarly associated with higher FSH levels in both young and older women.
Similarly, longer duration of HT use was positively associated with FSH levels in
younger and older women, though a dose-response relation was not observed, likely due
to low power for these comparisons.
Because associations of reproductive factors with FSH levels could potentially be
modified by adiposity, we then stratified our population according to World Health
Organization BMI category (<25.0 (normal weight), 25.0-29.0 (overweight) or ≥ 30.0
(obese). We did not observe evidence of effect modification by BMI for any of the
factors evaluated.
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CHAPTER 4
DISCUSSION
In this study of older postmenopausal women, we observed significant
associations between several reproductive factors and FSH levels. Women with both a
high parity (3 or more births) and a later age at first birth (25 or later) had mean FSH
levels that were significantly 7.6 IU/L lower than those of women with a lower parity (1
to 2 births) and a younger age at first birth (24 or less). Number of miscarriages was also
inversely correlated with FSH levels. Women reporting a long durations of OC and HT
use each had significantly higher mean FSH levels than women who had never used OCs
or HT. Importantly, these associations existed after adjustment for sex steroids, adiposity
measures, plasma lipids, blood pressure, and behavioral factors.
We found that parity was associated with lower FSH levels, while a long duration of
OCs and HT was associated with higher FSH levels. Given that both pregnancy and HT
are associated with estrogen exposure and suppression of FSH, it is surprising that these
associations are not similar. To our knowledge, an association between reproductive
factors and FSH, accounting for other factors including adiposity, hormones, and
behavioral factors, has not been observed before. While two previous studies of
reproductive factors and FSH levels suggested potential associations of pregnancy
history, both studies did not account for potential confounding by biochemical and
clinical factors. Consistent with our results showing lower mean FSH levels among
parous women, Chubak and et5 found that among 173 postmenopausal, sedentary,
overweight or obese women, nulliparous women had 19% higher FSH concentrations
than parous women (p=0.02), even after adjustment for age, body fat, alcohol
consumption, marital status, race, and number of ovaries remaining. Ness et al6 reported
10

that among 270 postmenopausal women, pregnancy termination was significantly related
to a rise in FSH one year after menopause (p=0.03), after adjustment for BMI, education,
oral contraceptive use, smoking, and alcohol consumption. However, this study focused
on younger, as opposed to older, postmenopausal women. Consistent with our results,
both of these studies found no association between age at menarche or age at last menses
and FSH levels.
Postmenopausal FSH levels may an important indicator of future disease risk.
Inverse associations of postmenopausal FSH levels with risk of T2D had been observed
in prior studies.1,7,8 In the KIHD population, women with FSH levels above the median
(50 IU/L) had approximately half the risk of developing T2D over 7 to 9 years of followup than women with lower levels.1 Furthermore, each 1 IU/L increase in FSH was
associated with a 1.9% lower prevalence of diabetes. Wang et al8 found that participants
with FSH levels of 50.2 IU/L or less had three times the risk of prevalent diabetes than
women with FSH levels of at least 82.5 IU/. Bjørnerem et al7 found that women with
diabetes had geometric mean postmenopausal FSH levels than were 7.4 IU/L lower than
levels healthy postmenopausal women (P=0.03).
When combined with results from previous studies, our results of lower FSH
levels among women with a high parity suggest that women with higher parity have a
higher risk of T2D. Based on the approximately 7 IU/L difference in FSH levels between
higher and lower parity women in our population, we would hypothesize that this
magnitude of difference would translate into a 13% lower diabetes risk (e.g., 7 IU/L*
1.9% decreased risk per unit). This is consistent with findings from multiple studies that
show that a high parity is associated with an increased risk of T2D.9–15 Most recently,
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Luo et al9 observed than women with five or more live births had 1.13 times the risk of
incident T2D compared to nulliparous women.
Hormone therapy use has been associated with lower diabetes risk in previous
studies. Pentti et al16 found that among 8483 postmenopausal women, past HT users had
a 19% lower risk of T2D (95% CI 0.57-1.16) and women who continuously used HT
during the follow-up period had a 69% lower risk of T2D (95% CI 0.16-0.60) compared
to never-users. Randomized trials17,18 have also shown that hormone therapy in
postmenopausal women is associated with a significantly lower incidence of T2D
compared to non-users, possibly mediated by a reduction in insulin resistance.17 These
findings are consistent with our results that a longer duration of HT is associated with
increased FSH levels and with results from previous studies that higher FSH levels are
associated with lower risk of T2D.1 Previous studies have shown that OC use is not
associated or is associated with an increased T2D risk. This association is opposite that of
HT and is not consistent with our findings relating a long duration of OC use to higher
FSH levels.
Inverse associations of FSH with insulin suggest that FSH may be related to TD2
through insulin resistance. Laboratory studies have observed FSH and/or FSH receptor
activity in extragonadal tissues, suggesting that actions of FSH may extend beyond its
functions in reproduction. Chu et al19 identified FSH in the rat pancreas, reporting
coexpression of FSH and FSH receptors in islet cells. FSH altered insulin and glucagon
secretion by pancreatic cells in vitro in a U-shaped manner. It is unknown whether FSH
may affect pancreatic insulin secretion in humans, and whether actions may vary by
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menopausal status. Effects of pregnancy on insulin sensitivity suggest that parity may be
related to T2D through the association of FSH and insulin.
The associations we observed between reproductive factors and FSH levels could
plausibly be explained by confounding by adiposity, as higher adiposity is associated
with higher endogenous estrogen production and consequently lower FSH levels.
However, since we adjusted for both BMI and waist to hip ratio, confounding by
adiposity and associations of adiposity with estrogens is unlikely to explain our findings.
Results from our stratified analyses do not give any indication that associations are
impacted by BMI or only observed among overweight and obese women.
Our study assessed FSH at a single time point and thus could not assess withinwomen variation in FSH. However, this limitation is unlikely to explain our findings, as
we would expect misclassification relating to the use of a single FSH measure to
attenuate association rather than exaggerate them. Because the KIHD study population is
very homogenous with respect to race and ethnicity, additional evaluation of these
relationships in diverse populations is needed. A strength of our study is the extensive
data on biochemical, behavioral, and clinical factors, allowing us to adjust beta estimates
for the effect of a large number of potential confounders. Associations persisted after
adjustment, suggesting that associations for FSH are not explained by these factors or by
other sex steroids. There may be residual confounding if some of the data on the
confounders is misclassified. As the women are 53 and older, some of the historical data
may be recalled incorrectly and some current data may be inaccurately reported.
However, since the covariates that are most likely to be confounders, including estradiol,
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testosterone, SHBG, and BMI were directly measured, confounding is unlikely to be an
issue.
To our knowledge, this is the first study of multiple reproductive factors and
postmenopausal FSH levels that accounted for other factors including adiposity,
hormones, and behavioral factors. We observed evidence of significantly lower FSH
levels among women with both a high parity and a later age at first birth, and significant
higher FSH levels among with with a long duration of OC or HT use. Number of
miscarriages was inversely associated with FSH levels. These associations were not
explained by estradiol, adiposity, and other factors. Additional studies of reproductive
factors and FSH in older postmenopausal women are needed to explore potential
underlying physiological explanations, and whether FSH also underlies associations of
reproductive factors with diabetes risk.
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Table 1: Follicle-stimulating hormone levels among women who were
not currently using hormone therapy, by age group, Kuopio Ischaemic
Heart Disease Risk Factor Study, 1998-2001
Follicle Simulating Hormone Level, IU/L
P value for mean
n Mean SD Min Median Max
IQR for mean
53-56 114 54.7 25.3
1.5
53.9
136.8 31.8
0.09
59-62 130 51.6 18.8
2.4
50.9
108.6 20.9
64-68 163 51.3 16.0
4.8
49.4
102.8 17.0
71-73 181 48.9 17.0
3.6
47.0
99.1
23.2
Abbreviations: SD, standard deviation; IQR, interquartile range.
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Table 2. Association of baseline characteristics with follicle-stimulating hormone levels
among women aged 53-73 years who were not using hormone therapy, Kuopio Ischemic Heart
Disease Risk Factor Study, 1998-2001
Follicle-Stimulating Hormone Level, IU/L
P value
n
β (SE)
Year of enrollment
1998
1999
2000
2001
Age, years
Age, years
53-56
59-62
64-68
71-73
Body mass indexa
Body mass index
Under/normal
Overweight
Obese
Waist:hip ratio
quartile 1
quartile 2
quartile 3
quartile 4
Physical activity, MET h/d
Alcohol intake, g/week
Pack-years of smokingb
Current smoking
no
yes
Systolic blood pressure, mm Hg
Diastolic blood pressure, mm Hg
Triglycerides, mmol/L
HDL cholesterol, mmol/L
LDL cholesterol, mmol/L
Estradiol, pmol/L
Testosterone, nmol/L
Sex hormone-binding globulin, nmol/L

164
220
186
18
588

3.28 (1.95)
0 (Referent)
5.49 (1.88)
14.55 (4.63)
-0.29 (0.12)

0.09
0.004
0.002
0.02

114
130
163
181
588

0 (Referent)
-2.82 (2.44)
-3.34 (2.32)
-5.78 (2.27)
-1.03 (0.14)

0.25
0.15
0.01
<0.0001

147
225
216
587
146
147
147
147
588
585
581

0 (Referent)
-5.50 (1.95)
-13.09 (1.97)
-64.56 (12.23)
0 (Referent)
-4.17 (2.17)
-7.72 (2.17)
-10.32 (2.17)
0.20 (0.12)
-0.02 (0.02)
-0.07 (0.12)

537
49
588
588
588
587
586
588
588
580

0 (Referent)
-2.18 (2.85)
-0.13 (0.04)
-0.09 (0.09)
-3.72 (1.18)
10.79 (2.47)
1.86 (0.87)
-0.13 (0.02)
-2.01 (0.51)
0.16 (0.03)

0.005
<0.0001
<0.0001
0.06
0.0004
<0.0001
0.09
0.31
0.57

0.44
0.004
0.30
0.002
<0.0001
0.03
<0.0001
<0.0001
<0.0001

Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; MET, metabolic
equivalent of task.
a
Weight (kg)/height (m) 2 .
b
Pack-years of cigarette smoking among ever smokers
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Table 3. Association of reproductive factors with follicle-stimulating hormone levels (IU/L) among women aged 53-73 years who were not using hormone
therapy, Kuopio Ischemic Heart Disease Risk Factor Study, 1998-2001
Model
a
b
c
Model 1
Model 2
Model 3
P Value
P Value
P Value
n
β (SE)
β (SE)
β (SE)
Parity, no. full-term pregnancies
587
-1.24 (0.47)
0.009
-0.92 (0.43)
0.04
-0.94 (0.44)
0.03
Parity, no. full-term pregnancies
0
76
1.89 (2.61)
0.47
2.52 (2.44)
0.30
2.12 (2.44)
0.39
1
94
0.65 (2.43)
0.79
2.09 (2.23)
1.06 (2.24)
0.35
0.64
2
175
0 (Referent)
0 (Referent)
0 (Referent)
3
128
-5.50 (2.21)
0.01
-4.01 (2.04)
-3.18 (2.05)
0.05
0.12
4+
114
-3.25 (2.28)
0.16
-0.81 (2.18)
-2.11 (2.24)
0.71
0.35
P for trend
0.006
0.02
0.02
Age at first birth, years
507
-0.34 (0.19)
0.07
-0.23 (0.17)
-0.31 (0.17)
0.18
0.07
Age at first birth, years
<20
50
0.53 (2.97)
0.86
-0.85 (2.69)
-0.63 (2.68)
0.75
0.81
20-24
253
0 (Referent)
0 (Referent)
0 (Referent)
25-29
145
-2.49 (2.00)
0.21
-1.90 (1.80)
-2.52 (1.80)
0.29
0.16
30+
59
-4.92 (2.77)
0.08
-3.40 (2.49)
-4.33 (2.52)
0.17
0.09
P for trend
0.04
0.16
0.06
Parity/age at first birth, years
0 births
76
-1.24 (2.71)
0.65
-0.11 (2.52)
-0.45 (2.52)
0.96
0.86
1-2 births/<25
132
0 (Referent)
0 (Referent)
0 (Referent)
3+ births/ <25
171
-6.35 (2.18)
0.004
-3.77 (2.03)
-3.99 (2.04)
0.06
0.05
1-2 births/ 25+
135
-5.42 (2.30)
0.02
-2.83 (2.10)
-3.72 (2.11)
0.18
0.08
3+ births/ 25+
69
-9.69 (2.79)
0.0006
-7.33 (2.61)
-7.65 (2.59)
0.01
0.003
Miscarriages, number
586
-2.74 (1.22)
0.03
-2.87 (1.11)
-2.92 (1.13)
0.01
0.01
Abortions, number
581
0.92 (1.89)
0.63
-0.70 (1.72)
-0.40 (1.73)
0.68
0.82
Abbreviations: SE, standard error.
a
Model 1 unadjusted.
b

Model 2 adjusted for year of enrollment, age (years), age (4 categories), estradiol (pmol/L), testosterone (nmol/L), and sex hormone binding-globulin
(nmol/L).
c

2

Model 3 further adjusted for body mass index (weight (kg)/height (m) ), body mass index (WHO categories), waist:hip ratio (quartiles), physical activity
(MET-hours/day), alcohol intake (g/week), pack-years of smoking (continuous), current smoking (yes,no), systolic and diastolic blood pressure (mm HG;
continuous), triglycerides (mmol/L), high-density lipoprotein cholesterol (mmol/L), low-density lipoprotein cholesterol (mmol/L).

17

Table 4. Association of reproductive factors with follicle-stimulating hormone levels among women aged 53-73 years who
were not using hormone therapy, Kuopio Ischemic Heart Disease Risk Factor Study, 1998-2001
Model
a

n
History of hysterectomy
No
Yes
History of oopherectomy
No
Yes

Model 1
P Value
β (SE)

Model 2 b
P Value
β (SE)

Model 3 c
P Value
β (SE)

448
135

0 (Referent)
-4.51 (1.86)

0.02

0 (Referent)
-1.85 (1.72)

0.28

0 (Referent)
-1.09 (1.73)

0.53

486
85

0 (Referent)
-1.21 (2.25)

0.59

0 (Referent)
-1.22 (2.07)

0.56

0 (Referent)
-0.12 (2.07)

0.95

History of gynaceological surgery
No
432
0 (Referent)
0 (Referent)
0 (Referent)
Yes
147
-3.21 (1.82)
0.08
-1.53 (1.67)
0.36
-0.79 (1.67)
0.64
Endometriosis
No
525
0 (Referent)
0 (Referent)
0 (Referent)
Yes
38
3.73 (3.23)
0.25
0.70 (2.94)
0.81
0.39 (2.99)
0.90
Uterine myomas
No
398
0 (Referent)
0 (Referent)
0 (Referent)
178
Yes
-3.25 (1.71)
0.06
-1.63 (1.57)
0.30
-0.94 (1.58)
0.55
Abbreviations: SE, standard error.
a
Model 1 unadjusted.
b
Model 2 adjusted for year of enrollment, age (years), age (4 categories), estradiol (pmol/L), testosterone (nmol/L), and sex
hormone binding-globulin (nmol/L).
c

Model 3 further adjusted for body mass index (weight (kg)/height (m) 2 ), body mass index (WHO categories), waist:hip ratio
(quartiles), physical activity (MET-hours/day), alcohol intake (g/week), pack-years of smoking (continuous), current smoking
(yes,no), systolic and diastolic blood pressure (mm HG; continuous), triglycerides (mmol/L), high-density lipoprotein
cholesterol (mmol/L), low-density lipoprotein cholesterol (mmol/L).
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Table 5. Association of reproductive factors with follicle-stimulating hormone levels among women
aged 53-73 years who were not using hormone therapy, Kuopio Ischemic Heart Disease Risk Factor
Study, 1998-2001
Model
Model 1a
Model 2b
Model 3c
β (SE) P Value
β (SE)
P Value
β (SE)
P Value
0.25 (0.52)
0.07 (0.47)
0.89
-0.28 (0.47) 0.56

n
Age at menarche, years
580
Age at menarche, years
<12
105 -0.18 (2.47) 0.94
1.43 (2.25)
13
140 0 (Referent)
0 (Referent)
14
128 -0.33 (2.34) 0.89
-0.08 (2.13)
15
113 -1.19 (2.42) 0.62
-0.31 (2.20)
16+
94 1.93 (2.55) 0.45
2.00 (2.31)
P for trend
0.66
0.89
Age at last menses, years 569 -0.15 (0.18) 0.40
-0.06 (0.16)
Age at last menses, years
<50
257 2.58 (1.79) 0.15
1.52 (1.62)
50-52
204 0 (Referent)
0 (Referent)
>52
127 -0.40 (2.16) 0.85
-0.31 (1.96)
P for trend
0.09
0.26
History of OC use
No
398 0 (Referent)
0 (Referent)
Yes
179 2.08 (1.72) 0.23
1.67 (1.70)
Duration OC use, years
0
398 0 (Referent)
0 (Referent)
<1
38 1.38 (3.24) 0.67
0.85 (3.10)
1-3
65 0.94 (2.55) 0.71
2.39 (2.42)
4-6
41 -1.27 (3.13) 0.69
-1.93 (2.89)
7+
35 8.90 (3.36) 0.01
5.41 (3.12)
P for trend
0.04
0.23
Past HT use
No
396 0 (Referent)
0 (Referent)
Yes
180 2.14 (1.68) 0.20
1.20 (1.53)
Duration HT use, years
0
393 0 (Referent)
0 (Referent)
<1
56 -0.86 (2.72) 0.75
-1.28 (2.45)
1-3
59 1.04 (2.66) 0.70
-1.94 (2.44)
4-6
31 8.16 (3.55) 0.02
8.12 (3.20)
7+
33 7.28 (3.45) 0.04
7.36 (3.17)
P for trend
0.005
0.003
Abbreviations: SE, standard error; OC, oral contraceptive; HT, hormone

0.52
0.97
0.89
0.39
0.73
0.35
0.87

0.33

0.78
0.32
0.50
0.08

0.43

1.57 (2.27)
0 (Referent)
-1.42 (2.13)
-1.21 (2.21)
0.49 (2.31)
0.51
-0.14 (0.16)

0.49

2.48 (1.63)
0 (Referent)
0.08 (1.97)
0.11

0.13

0 (Referent)
2.07 (1.73)
0 (Referent)
-0.10 (3.23)
3.14 (2.41)
-2.13 (2.89)
6.79 (3.13)
0.11
0 (Referent)
1.39 (1.54)

0 (Referent)
-0.98 (2.44)
-1.12 (2.44)
8.65 (3.23)
7.52 (3.21)
0.003
therapy.
0.60
0.43
0.01
0.02

0.51
0.58
0.83
0.38

0.97

0.23

0.97
0.19
0.46
0.03

0.37

0.69
0.65
0.01
0.02

a

Model 1 unadjusted.

b

Model 2 adjusted for year of enrollment, age (years), age (4 categories), estradiol (pmol/L),
testosterone (nmol/L), and sex hormone binding-globulin (nmol/L).
c

Model 3 further adjusted for body mass index (weight (kg)/height (m) 2), body mass index (WHO
categories), waist:hip ratio (quartiles), physical activity (MET-hours/day), alcohol intake (g/week), packyears of smoking (continuous), current smoking (yes,no), systolic and diastolic blood pressure (mm HG;
continuous), triglycerides (mmol/L), high-density lipoprotein cholesterol (mmol/L), low-density
lipoprotein cholesterol (mmol/L).
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Table 6. Association of reproductive factors with follicle-stimulating hormone levels among women aged 5373 years who were not using hormone therapy, stratified by age group, Kuopio Ischemic Heart Disease Risk
Factor Study, 1998-2001
Age Group
53-62 Years
Parity, no. full-term pregnancies
Parity, no. full-term pregnancies
0
1
2
3
4+
Age at first birth, years
Age at first birth, years
<20
20-24
25-29
30+
Parity/age at first birth, years
0 births
1-2 births/<25
3-4 births/ <25
1-2 births/ 25+
3-4 births/ 25+
History of OC use
No
Yes
Duration OC use, years
0
<1
1-3
4-6
7+
Past HT Use
No
Yes
Duration HT use, years
0
<1
1-3
4-6
7+

64-73 Years

n
244

β (SE)a
-2.64 (1.00)

P value
0.01

n
343

β (SE)a
-0.44 (0.48)

P value
0.35

22
37
107
54
24
221

6.79 (4.59)
0.25 (3.79)
0 (Referent)
-8.51 (3.37)
-5.76 (4.53)
-0.58 (0.32)

0.14
0.95

54
57
68
74
90
286

1.08 (2.97)
1.90 (2.91)
0 (Referent)
1.36 (2.71)
-0.58 (2.73)
-0.15 (0.20)

0.72
0.51

23
119
51
28

-6.16 (4.53)
0 (Referent)
-7.46 (3.32)
-7.31 (4.29)

0.18

27
134
94
31

3.89 (3.35)
0 (Referent)
0.39 (2.10)
-1.65 (3.14)

0.25

22
79
63
64
15

2.92 (4.65)
0 (Referent)
-9.21 (3.30)
-8.39 (3.32)
-18.71 (5.44)

0.53

0.95 (3.04)
0 (Referent)
1.41 (2.70)
1.73 (2.84)
-1.34 (3.05)

0.75

0.006
0.012
0.0007

54
53
108
71
54

120
120

0 (Referent)
1.92 (2.70)

0.48

278
59

0 (Referent)
3.27 (2.41)

0.17

120
29
40.000
27
24

0 (Referent)
1.63 (4.61)
1.86 (3.76)
-3.15 (4.27)
7.48 (4.46)

0.72
0.62
0.46
0.10

278
9
25
14
11

0 (Referent)
0.52 (5.70)
5.17 (3.29)
-1.33 (4.38)
7.10 (5.23)

0.93
0.12
0.76
0.18

162
80

0 (Referent)
-2.43 (2.68)

0.37

234
100

0 (Referent)
4.42 (1.89)

0.02

158
26
21
20
15

0 (Referent)
-5.70 (4.15)
-10.47 (4.80)
3.73 (4.68)
10.83 (5.52)

0.17
0.03
0.43
0.05

235
30
38
11
18

0 (Referent)
3.79 (2.99)
4.47 (2.78)
12.73 (4.88)
4.15 (3.90)

0.21
0.11
0.01
0.29

0.01
0.20
0.07

0.03
0.09

0.62
0.83
0.46

0.85
0.60

0.60
0.54
0.66

Abbreviations: SE, standard error; OC, oral contraceptive; HT, hormone therapy.
a

Results adjusted for year of enrollment, body mass index (weight (kg)/height (m) 2), body mass index (WHO
categories), waist:hip ratio (quartiles), physical activity (MET-hours/day), alcohol intake (g/week), pack-years
of smoking (continuous), current smoking (yes,no), systolic and diastolic blood pressure (mm HG;
continuous), triglycerides (mmol/L), high-density lipoprotein cholesterol (mmol/L), low-density lipoprotein
cholesterol (mmol/L), estradiol (pmol/L), testosterone (nmol/L), and sex hormone binding-globulin (nmol/L).
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Table 7. Association of reproductive factors with follicle-stimulating hormone levels among women aged 53-73 years who were not using hormone
therapy, stratified by Body Mass Index, Kuopio Ischemic Heart Disease Risk Factor Study, 1998-2001
Body Mass Indexa
<25.0 (Normal-Weight, n=147)
25.0-29.9 (Overweight, n=225)
≥ 30.0 (obese, n=216)
Parity, no. full-term pregnancies
Parity, no. full-term pregnancies
0
1
2
3
4+
Age at first birth, years
Age at first birth, years
<20
20-24
25-29
30+
Parity/age at first birth, years
0 births
1-2 births/<25
3-4 births/ <25
1-2 births/ 25+
3-4 births/ 25+
Miscarriages, number
Abortions, number
History of hysterectomy
No
Yes
History of oopherectomy
No
Yes

β (SE)b
-0.76 (1.26)

P value
0.55

β (SE)b
-1.37 (0.68)

P value
0.04

β (SE)b
-0.94 (0.68)

P value
0.17

-4.82 (6.45)
-1.05 (4.97)
0 (Referent)
-11.92 (5.68)
-2.70 (5.54)
-0.30 (0.45)

0.46
0.83

2.84 (3.98)
0.97 (3.97)
0 (Referent)
-2.63 (3.01)
-5.27 (4.01)
-0.52 (0.27)

0.48
0.81

6.55 (3.88)
1.21 (3.65)
0 (Referent)
-1.41 (3.11)
0.22 (3.37)
-0.20 (0.28)

0.09
0.74

-14.19 (7.43)
0 (Referent)
-10.79 (4.55)
-4.68 (6.09)

0.06

1.39 (4.23)
0 (Referent)
0.89 (2.96)
-8.12 (4.12)

0.74

3.23 (4.32)
0 (Referent)
-2.42 (2.86)
-2.83 (3.90)

0.46

-8.89 (6.38)
0 (Referent)
-8.23 (5.33)
-7.77 (4.75)
-16.87 (6.51)
-2.38 (2.16)
7.46 (4.34)

0.17

0.46

0.36
0.75
0.10
0.02
0.57

2.90 (3.96)
0 (Referent)
-4.16 (3.13)
-6.12 (3.39)
-4.81 (4.08)
-2.48 (1.92)
-3.49 (2.75)

0.04
0.63
0.51

0.02
0.44

0.43
0.19
0.06

0.76
0.050

0.40
0.47

0.13
0.10
0.01
0.27
0.09

1.84 (4.21)
0 (Referent)
-3.28 (3.55)
-1.19 (3.75)
-7.21 (4.35)
-5.16 (2.15)
-1.61 (2.81)

0 (Referent)
-4.23 (5.02)

0.40

0 (Referent)
-1.38 (2.70)

0.61

0 (Referent)
2.29 (2.64)

0.39

0 (Referent)
-3.39 (5.88)

0.57

0 (Referent)
-0.34 (3.22)

0.92

0 (Referent)
2.96 (3.23)

0.36
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0.66

0.65
0.95
0.47

0.18
0.07
0.24
0.20
0.21

Table 7 Continued.
Body Mass Indexa
25.0-29.9 (Overweight, n=225)

<25.0 (Normal-Weight, n=147)
β (SE)
History of gynaceological surgery
No
Yes
Endometriosis
No
Age at menarche, years
Age at menarche, years
<12
13
14
15
16+
Age at last menses, years
Age at last menses, years
<50
50-52
>52
History of OC use
No
Yes
Duration OC use
0
<1
1-3
4-6
7+
Past HT Use
No
Yes

b

β (SE)b

P value

0 (Referent)
-1.80 (2.58)

0.49

0 (Referent)
2.51 (2.64)

0.34

0 (Referent)
0.40 (0.83)

0.63

0 (Referent)
0.28 (0.77)

0.72

β (SE)

0 (Referent)
-2.91 (4.79)

0.54

0 (Referent)
-2.17 (1.13)

0.06

-1.05 (6.04)
0 (Referent)
-11.35 (5.41)
-8.97 (5.37)
-12.56 (5.38)
-0.02 (0.46)

0.86

-3.31 (3.97)
0 (Referent)
-3.00 (5.03)

0.41

≥ 30.0 (obese, n=216)

P value

P value

b

2.08 (3.99)
0 (Referent)
-0.72 (3.38)
-4.47 (3.76)
5.85 (3.59)
0.08 (0.25)

0.60

3.12 (3.31)
0 (Referent)
0.37 (3.47)
4.76 (3.49)
2.93 (4.21)
-0.40 (0.26)

0.35

0.34

0.55

2.57 (2.68)
0 (Referent)
1.48 (3.31)

0.01

0.66

6.71 (2.53)
0 (Referent)
1.54 (2.87)

0 (Referent)
6.50 (4.30)

0.13

0 (Referent)
-0.58 (2.86)

0.84

0 (Referent)
3.68 (2.77)

0.18

0 (Referent)
8.67 (7.83)
7.72 (6.61)
2.48 (6.19)
10.13 (7.74)

0.27
0.25
0.69
0.19

0 (Referent)
-8.74 (5.22)
3.37 (3.89)
-5.24 (4.94)
4.47 (5.42)

0.10
0.39
0.29
0.41

0 (Referent)
7.62 (5.24)
3.06 (3.77)
-4.21 (5.12)
8.82 (4.94)

0.15
0.42
0.41
0.08

0 (Referent)
9.25 (3.71)

0.01

0 (Referent)
-2.22 (2.54)

0.38

0 (Referent)
1.77 (2.48)

0.48

0.04
0.10
0.02
0.97

22

0.83
0.24
0.10
0.74

0.91
0.17
0.49
0.12

0.59

Table 7 Continued.
<25.0 (Normal-Weight, n=147)
β (SE)

b

Body Mass Indexa
25.0-29.9 (Overweight, n=225)
β (SE)

P value

b

≥ 30.0 (obese, n=216)

P value

β (SE)b

P value

0.19
0.08
0.96
0.13

0 (Referent)
2.17 (3.49)
-3.92 (4.13)
3.72 (5.70)
14.80 (8.36)

0.53
0.34
0.51
0.08

Duration HT use, years
0
0 (Referent)
0 (Referent)
<1
0.84 (6.34)
0.89
-5.33 (4.08)
1-3
13.59 (5.55)
0.02
-6.99 (3.98)
4-6
30.70 (7.28)
<0.0001
0.23 (4.98)
7+
1.68 (7.42)
0.82
6.4 (4.25)
Abbreviations: SE, standard error; OC, oral contraceptive; HT, hormone therapy.
a

Weight (kg)/height (m) 2 .
b
Results were adjusted for year of enrollment, age (years), age (4 categories), waist:hip ratio (quartiles), physical activity (MET-hours/day), alcohol
intake (g/week), pack-years of smoking (continuous), current smoking (yes,no), systolic and diastolic blood pressure (mm HG; continuous),
triglycerides (mmol/L), high-density lipoprotein cholesterol (mmol/L), low-density lipoprotein cholesterol (mmol/L), estradiol (pmol/L),
testosterone (nmol/L), and sex hormone binding-globulin (nmol/L).
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